Janux Therapeutics - Public Comps and Valuation Multiples

Janux Therapeutics Overview

About Janux Therapeutics

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Founded

2017

HQ

Employees

Website

januxrx.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $5.2M

LTM EBITDA -$154M

EV

$450M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Janux Therapeutics Financials

As of September 2025, Janux Therapeutics reported last 12-month revenue of $5.2M and EBITDA of -$154M.

In the same period, Janux Therapeutics achieved -$121M in LTM net income.

See Janux Therapeutics valuation multiples based on analyst estimates

Janux Therapeutics P&L

In the most recent fiscal year, Janux Therapeutics reported revenue of $10.6M and EBITDA of -$96.8M.

Janux Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Janux Therapeutics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$5.2M	XXX	$10.6M	XXX	XXX	XXX
Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
Gross Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA	-$154M	XXX	-$96.8M	XXX	XXX	XXX
EBITDA Margin	-2932%	XXX	-914%	XXX	XXX	XXX
EBIT	-$159M	XXX	-$98.8M	XXX	XXX	XXX
EBIT Margin	-3025%	XXX	-934%	XXX	XXX	XXX
Net Profit	-$121M	XXX	-$69.0M	XXX	XXX	XXX
Net Margin	-2315%	XXX	-652%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Janux Therapeutics including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $5.2M. EBITDA for the last twelve months was -$154M. In the most recent fiscal year, Janux Therapeutics achieved $10.6M in revenue and -$96.8M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$5.2M	Analyst estimates available to subscribers	$10.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	NaN% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$154M	Analyst estimates available to subscribers	-$96.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-2932.0% EBITDA margin	Analyst estimates available to subscribers	-914.1% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$159M	Analyst estimates available to subscribers	-$98.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-3025.4% EBIT margin	Analyst estimates available to subscribers	-933.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$121M	Analyst estimates available to subscribers	-$69.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-2314.7% net profit margin	Analyst estimates available to subscribers	-651.6% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Janux Therapeutics

This financial data table provides comprehensive performance metrics for Janux Therapeutics, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Janux Therapeutics generated $5.2M in revenue over the last twelve months.
The company achieved -$154M in EBITDA over the last twelve months.
Net income over the last twelve months reached -$121M.

Fiscal Year Performance

In the most recent fiscal year, Janux Therapeutics reported $10.6M in total revenue.
Fiscal year EBITDA was -$96.8M.
The company maintained a gross profit margin of NaN% in the most recent fiscal year.
EBITDA margin for the fiscal year was -914.1%.
Net profit margin reached -651.6% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Janux Therapeutics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Janux Therapeutics Stock Performance

Janux Therapeutics has current market cap of $1.4B, and EV of $450M.

Market Cap Evolution

Janux Therapeutics Stock Data

As of October 2, 2025, Janux Therapeutics's stock price is $24.

See Janux Therapeutics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$450M	$1.4B	XXX	XXX	XXX	XXX	$-2.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Janux Therapeutics Valuation Multiples

Janux Therapeutics's trades at 42.5x EV/Revenue multiple, and -4.7x EV/EBITDA.

See valuation multiples for Janux Therapeutics and 15K+ public comps

Janux Therapeutics Financial Valuation Multiples

As of October 2, 2025, Janux Therapeutics has market cap of $1.4B and EV of $450M.

Equity research analysts estimate Janux Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Janux Therapeutics has a P/E ratio of -11.7x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.4B	XXX	$1.4B	XXX	XXX	XXX
EV (current)	$450M	XXX	$450M	XXX	XXX	XXX
EV/Revenue	85.8x	XXX	42.5x	XXX	XXX	XXX
EV/EBITDA	-2.9x	XXX	-4.7x	XXX	XXX	XXX
EV/EBIT	-2.8x	XXX	-4.6x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-11.7x	XXX	-20.6x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-10.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Janux Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Janux Therapeutics Margins & Growth Rates

Janux Therapeutics's last 12 month revenue growth is -1%

Janux Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.4M for the same period.

Janux Therapeutics's rule of 40 is -880% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Janux Therapeutics's rule of X is -2935% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Janux Therapeutics and other 15K+ public comps

Janux Therapeutics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	-1%	XXX	-26%	XXX	XXX	XXX
EBITDA Margin	-2932%	XXX	-914%	XXX	XXX	XXX
EBITDA Growth	25%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-880%	XXX	-915%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	-2935%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.4M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	646%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	1034%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial